/PRNewswire/ -- Stroke is now the fourth leading cause of death in the United States, down from the third place ranking it has held for decades, according to preliminary 2008 death statistics released today by CDC's National Center for Health Statistics. While deaths from stroke and several other chronic diseases are down, deaths due to chronic lower respiratory disease increased in 2008.
There were 133,750 deaths from stroke in 2008. Age-adjusted death rates from stroke declined 3.8 percent between 2007 and 2008. Meantime, there were 141,075 deaths from chronic lower respiratory disease, and the death rate increased by 7.8 percent.
Some of the increase in deaths may be due to a modification made by the World Health Organization in the way deaths from chronic lower respiratory diseases are classified and coded. The National Center for Health Statistics will conduct a thorough analysis on this change and its effect on the chronic lower respiratory disease category before the final 2008 deaths data are released.
"Deaths: Preliminary Data for 2008," also finds that life expectancy at birth dropped slightly to 77.8 years from 77.9 years in 2007. Life expectancy was down by one-tenth of a year (a little over a month) for both men and women. However, black males had a record high life expectancy in 2008 of 70.2 years – up from 70 years in 2007. The life expectancy gap between the white and black populations was 4.6 years in 2008, a decrease of two-tenths of a year from 2007.
The data are based on 99 percent of death certificates reported to NCHS through the National Vital Statistics System from all 50 states, the District of Columbia and U.S. territories.
Other findings:
* Heart disease and cancer, the two leading causes of death, still accounted for nearly half (48 percent) of all deaths in 2008.
* In addition to stroke, mortality rates declined significantly for five of the other 15 leading causes of death: accidents/unintentional injuries (3.5 percent), homicide (3.3 percent), diabetes (3.1 percent), heart disease (2.2 percent), and cancer (1.6 percent).
* In addition to chronic lower respiratory disease, death rates increased significantly in 2008 for Alzheimer's disease (7.5 percent), influenza and pneumonia (4.9 percent), high blood pressure (4.1 percent), suicide (2.7 percent), and kidney disease (2.1 percent).
* The preliminary infant mortality rate for 2008 was 6.59 infant deaths per 1,000 live births, a 2.4 percent decline from the 2007 rate of 6.77 and an all-time record low. Birth defects were the leading cause of infant death in 2008, followed by disorders related to preterm birth and low birth weight. Sudden infant death syndrome (SIDS) was the third leading cause of infant death in the United States.
* Overall, there were 2,473,018 deaths in the United States in 2008, according to the preliminary deaths report -- 49,306 more deaths than the 2007 total.
* The age-adjusted death rate for the U.S. population fell to 758.7 deaths per 100,000 in 2008 compared to the 2007 rate of 760.2.
------
Community News You Can Use
Click to read MORE news:
www.GeorgiaFrontPage.com
Twitter: @gafrontpage & @TheGATable @HookedonHistory
www.ArtsAcrossGeorgia.com
Twitter: @artsacrossga, @softnblue, @RimbomboAAG
www.FayetteFrontPage.com
Twitter: @FayetteFP
Thursday, December 9, 2010
Stroke Drops to Fourth Leading Cause of Death in 2008
Posted by
Georgia Front Page.com
at
6:31 PM
0
comments
Labels: cdc, death, decline, fayette front page, georgia, georgia front page, ranking, report, respiratory, statistics, stroke
Tuesday, October 19, 2010
FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
/PRNewswire/ -- The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).
Atrial fibrillation, which affects more than 2 million Americans, involves very fast and uncoordinated contractions of the heart's two upper heart chambers (atria) and is one of the most common types of abnormal heart rhythm.
"People with atrial fibrillation are at a higher risk of developing blood clots, which can cause a disabling stroke if the clots travel to the brain," said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDA's Center for Drug Evaluation and Research.
Pradaxa is an anticoagulant that acts by inhibiting thrombin, an enzyme in the blood that is involved in blood clotting. The safety and efficacy of Pradaxa were studied in a clinical trial comparing Pradaxa with the anticoagulant warfarin. In the trial, patients taking Pradaxa had fewer strokes than those who took warfarin.
"Unlike warfarin, which requires patients to undergo periodic monitoring with blood tests, such monitoring is not necessary for Pradaxa," Stockbridge says.
As with other approved anti-clotting drugs, bleeding, including life-threatening and fatal bleeding, was among the most common adverse reactions reported by patients treated with Pradaxa. Gastrointestinal symptoms, including an uncomfortable feeling in the stomach (dyspepsia), stomach pain, nausea, heartburn, and bloating also were reported.
Pradaxa was approved with a Medication Guide that informs patients of the risk of serious bleeding. The guide will be distributed each time a patient fills a prescription for the medication.
Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals Inc. of Ridgefield, Conn., will be available in 75 milligram and 150 milligram capsules.
-----
Community News You Can Use
Click to read MORE news:
www.GeorgiaFrontPage.com
Twitter: @gafrontpage & @TheGATable @HookedonHistory
www.ArtsAcrossGeorgia.com
Twitter: @artsacrossga, @softnblue, @RimbomboAAG
www.FayetteFrontPage.com
Twitter: @FayetteFP
Posted by
Georgia Front Page.com
at
7:21 PM
0
comments
Labels: approval, atrial fibrillation, blood, blood clots, fayette front page, fda, georgia, georgia front page, heart, heart rhythms, pradexa, stroke
Piedmont Fayette Hospital and Piedmont Heart Institute Physicians Partner with US AGAINST ATHERO to Educate on Heart Disease
Piedmont Fayette Hospital and Piedmont Heart Institute Physicians have teamed up with US AGAINST ATHERO, to bring the Artery Explorer experience to Piedmont Fayette Hospital at 1255 Highway 54 West in Fayetteville, Ga. In addition to this unique educational experience, visitors will have a chance to have their blood pressure checked and learn their body mass index (BMI). The event is Tuesday, October 26 from 11 a.m. to 5 p.m. and Wednesday, October 27 from 1 p.m. to 6 p.m.
As part of US AGAINST ATHERO, the Artery Explorer is touring the country to increase awareness of atherosclerosis—the dangerous buildup of plaque in the arteries. This incredible virtual experience allows viewers to surf through arteries on a journey deep inside the body. The movie demonstrates how risk factors like high levels of bad cholesterol, smoking and high blood pressure can contribute to the buildup of plaque in arteries.
Coronary heart disease and stroke kill more Americans every year than all cancers combined. Atherosclerosis, or athero for short, is often the leading cause. It is the progressive buildup of plaque in the arteries linked to about one in four deaths in the United States each year. For more information, call 770.719.6060 or visit athero.com.
---
Community News You Can Use
Click to read MORE news:
www.GeorgiaFrontPage.com
Twitter: @gafrontpage & @TheGATable @HookedonHistory
www.ArtsAcrossGeorgia.com
Twitter: @artsacrossga, @softnblue, @RimbomboAAG
Facebook: http://facebook.com/ArtsAcrossGA
www.FayetteFrontPage.com
Twitter: @FayetteFP
Thursday, January 14, 2010
FDA Updates Earlier Guidance on Respiratory Treatment Spiriva HandiHaler
The U.S. Food and Drug Administration today announced that data from a recent review of the Spiriva HandiHaler, a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD), do not support an increased risk of stroke, heart attack, or death in patients using the medicine.
COPD is a serious and chronic lung disease that restricts air flow in the lungs resulting in shortness of breath. In the United States, COPD includes two main conditions – emphysema and chronic bronchitis. Spiriva HandiHaler consists of capsules and an inhalation device approved for once daily use in COPD.
A March 2008 FDA Early Communication had described data submitted by the manufacturer of Spiriva HandiHaler as suggesting a small increased risk of stroke in patients treated with tiotropium, the medicine’s active ingredient. In October 2008, an Updated Early Communication highlighted two additional publications suggesting an increased risk of stroke, heart attack, and death in patients using tiotropium.
Today’s update of those communications is based on an FDA review of the Understanding the Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) study that compared Spiriva HandiHaler with a placebo in 5,992 COPD patients. In November 2009, the FDA Pulmonary – Allergy Drugs Advisory Committee also reviewed the data and voted that findings from the UPLIFT study resolved the potential safety concerns for Spiriva Handihaler.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter: @GAFrontPage
Friday, February 20, 2009
Clot-Buster Boosts Survival, Decreases Disability for Deadly Subset of Stroke
New results from a multicenter study led by Johns Hopkins show that patients who got an experimental clot-busting treatment for a particularly lethal form of stroke were not only dramatically more likely to survive but also continued to shed lingering disabilities six months later. The findings, announced at the International Stroke Conference in San Diego on Feb. 19, are likely to build support for the use of tissue plasminogen activator (tPA) in patients with intracranial hemorrhage, a treatment-resistant form of stroke marked by brain bleeding.
Last May, study leader Daniel Hanley, M.D., professor of neurology at the Johns Hopkins School of Medicine, and his colleagues reported early findings among 52 intracranial hemorrhage (ICH) patients treated with tPA given by catheter directly into patients' brains to bathe and destroy blood clots with this clot-busting agent. The researchers worked with patients at 38 study sites scattered throughout the United States, as well as in Canada, Germany and Finland.
The treatment, developed by Hanley's team, gives low doses of tPA over several days after strokes involving intracranial hemorrhage.
This drug normally isn't recommended for conditions that involve bleeding, such as ICH, because it can increase the risk of further hemorrhage. However, since tPA is effective at breaking up clots in other conditions, such as heart attacks and other types of strokes, Hanley and his colleagues have been studying its safety and efficacy for treating ICH.
Early results from this study using information collected 30 days after tPA treatment showed that about 80 percent survived, compared to data from previous studies showing that about 80 percent of untreated ICH patients die. In the new study, the researchers report on the patients' progress six months after treatment using assessments for overall levels of disability as well as their skill in accomplishing specific tasks often affected by stroke, such as dressing, bathing or walking.
The researchers found that about 10 percent of patients had no lingering disability after six months. Another 40 percent had only mild to moderate disability and were independently caring for themselves at home by 180 days, but required assistance with everyday tasks such as lifting heavy objects. Even patients who were initially more severely disabled continued to improve months after treatment, with the majority scoring lower on disability assessments after six months compared to the same assessments taken at 30 days.
"We're painting a pretty good picture for quality of life after our treatment for ICH," Hanley says. "Survival doesn't have to mean just getting by-we're showing that it can mean truly living again."
Hanley adds that patients, families, physicians and ethicists worry deeply about the impact of stroke treatments that keep patients alive but leave them with a sharply curbed quality of life. "Our new treatment appears to greatly increase patients' chances for survival and quality of life similar to what they experienced before they had their stroke," he says.
Intracerebral hemorrhage, or ICH, causes blood to pool and clot inside the brain's interior cavities, building up pressure within the brain. The higher pressure, along with inflammation caused by chemicals in the trapped blood, can irreversibly damage the brain, usually leading to death or extreme disability.
Hanley and colleagues, with a clinical planning grant from the National Institute of Neurological Diseases and Stroke will design a pivotal test to assess the value of tPA therapy on a much larger group of ICH patients. They expect to start this clinical trial imminently..
Other Johns Hopkins researchers who participated in this study include Wendy Ziai, M.D.; Ricardo Carhuapoma, M.D.; Neal Naff, M.D.; Becky Sullivan, M.B.A.; Timothy Morgan, B.S.; Eric Melnychuk, B.A., E.M.T.-B; Susan Rice, R.N., M.P.H., C.C.R.P.; Amber Stahl, B.A.; Shannon LeDroux, B.S.; Amanda Bistran, B.S.; and Karen Lane, C.M.A., C.C.R.P.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
7:57 AM
0
comments
Labels: atlanta, brain, clot buster, fayette front page, georgia, georgia front page, johns hopkins, plasminogen, stroke, study, survive, treatment
Tuesday, January 20, 2009
Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research
/PRNewswire/ -- Stents can be placed in the brain to treat a stroke as it's occurring, suggests preliminary data being presented at the 21st Annual International Symposium on Endovascular Therapy (ISET).
Stents have long been used to open up blocked blood vessels in the heart to prevent heart attacks and in the neck to prevent strokes. More recently stents have been used in the heart to treat occurring heart attacks by opening up the blocked arteries. This early research suggests stents also can be used to treat occurring strokes, by opening up blocked arteries in the brain.
Treatments for ischemic stroke currently include delivering clot-busting drugs to the blockage through the veins or directly into the clot through an artery, or by removing the clot with a tiny corkscrew-like device or vacuuming it out. But early research suggests stents may work better than those treatments.
"Most patients had significant improvement; for instance, they could go home rather than having to be placed in a nursing home, which is pretty dramatic," said L. Nelson Hopkins, M.D., professor and chairman of neurosurgery and professor of radiology at the State University of New York at Buffalo, who is presenting the data at ISET. "Stents seem to work when clot-busters or other mechanical devices can't."
The third-leading cause of death in the U.S., stroke is called a brain attack because blood flow and oxygen to part of the brain is cut off. About 85 percent of strokes are ischemic, meaning they're caused by a blocked blood vessel. About 700,000 people suffer an ischemic stroke every year. The remaining 15 percent of strokes are hemorrhagic and are caused by a broken blood vessel. The lack of blood flow and oxygen to the site of the stroke causes the brain tissue to die. About a quarter of people who suffer a stroke die. Another third are severely disabled and may be paralyzed or lose the ability to speak or remember.
SUNY Buffalo researchers are reporting preliminary results on 16 patients who received stents to treat their strokes as part of a single center Investigational Device Exemption (IDE) from the FDA, with Elad Levy, M.D., as the principal investigator. Stents were placed and opened blocked arteries in the brain in all patients (100 percent) and 11 patients (69 percent) had significant improvement in their stroke symptoms.
Clot-busting drugs only work about half of the time because the blockage can be sticky and adhere to the wall of the artery, making it difficult to break up, said Dr. Hopkins.
Researchers used computed tomography (CT) perfusion to determine if the use of a stent would be beneficial. "With CT perfusion we can tell if the brain is dead or alive," said Dr. Hopkins. "Some patients experience brain death within an hour; others can have a viable brain 24 hours after the stroke starts." In those cases, it may still be possible to place a stent.
Tiny cage-like cylinders, stents are placed minimally invasively by threading a small tube, or catheter, through the arteries to the site of the blockage. A tiny balloon is inflated to open up the blockage. A collapsed stent is then placed at the site, where it expands and acts like scaffolding to keep the artery open.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
6:41 AM
0
comments
Labels: atlanta, blocked blood vessel, fayette front page, georgia, georgia front page, heart attacks, ischemic stroke, research, stent, stroke, SUNY
Tuesday, November 25, 2008
Do You Know You're Having a Stroke?
/PRNewswire-USNewswire/ -- A Mayo Clinic study shows a majority of stroke patients don't think they're having a stroke -- and as a result -- delay seeking treatment until their condition worsens. The findings appear in the current issue of Emergency Medicine Journal at http://emj.bmj.com/.
Researchers studied 400 patients who were diagnosed at Mayo Clinic's emergency department with either acute ischemic stroke or a transient ischemic attack (TIA), a temporary interruption of blood flow to part of the brain.
Less than half of the patients -- 42 percent -- thought they were having a stroke. In fact, most in the study did not go to the emergency room when symptoms appeared. The median time from onset of symptoms to arrival at the hospital was over three and a half hours. Most said they thought the symptoms would simply go away. The delay in seeking medical help was the same among men and women.
When asked how they knew about stroke symptoms, nearly one-fifth said they thought a stroke always came on gradually. Just over half (51.9 percent) said they thought that seeking medical care immediately was important.
Significance of the findings
"Time is crucial in treating stroke," says Latha Stead, M.D., emergency medicine specialist and lead author of the study. "Each individual's medical background differs and affects recovery, but in general the sooner a patient experiencing a stroke reaches emergency care, the more likely the stroke can be limited and the condition managed to prevent further damage and improve recovery." The researchers say their findings clearly indicate that better public understanding of stroke symptoms will lead to a faster response and better outcomes.
What you should know
Strokes can happen quickly or can occur over several hours, with the condition continually worsening. The thrombus or clot that is causing the stroke can frequently be dissolved or disintegrated so blood can again flow to the brain. In such cases, immediate treatment can mean the difference between a slight injury and a major disability. Interestingly only 20.8 percent of the participants knew about such treatment. By use of stents, medications and other technology, physicians can stop a stroke from spreading and greatly limit damage. Stroke symptoms include:
* Sudden numbness, weakness, or paralysis of your face, arm or leg -- usually on one side of the body
* Sudden difficulty speaking or understanding speech (aphasia)
* Sudden blurred, double or decreased vision
* Sudden dizziness, loss of balance or loss of coordination
* A sudden, severe "bolt out of the blue" headache or an unusual headache, which may be accompanied by a stiff neck, facial pain, pain between your eyes, vomiting or altered consciousness
* Confusion or problems with memory, spatial orientation or perception
In such cases, a stroke gives no warning. But one possible sign of an impending stroke is a TIA. The signs and symptoms of TIA are the same as for a stroke, but they last for a shorter period -- several minutes to a few hours -- and then disappear, without leaving apparent permanent effects. You may have more than one TIA, and the signs and symptoms may be similar or different. A TIA indicates a serious risk that a full-blown stroke may follow.
Other Mayo researchers involved in the study were Lekshmi Vaidyanathan, M.B.B.S.; Maria Bellolio, M.D.; Rahul Kashyap, M.B.B.S.; Anjali Bhagra, M.B.B.S.; Rachel Gilmore, M.B.B.Ch.; Wyatt Decker, M.D.; Sailaja Enduri, M.B.B.S.; Shaily Mishra, Ph.D.; Helen Wood, R.N.; Ayman Yassa, M.D.; Ann Hoff, M.D.; and Robert Brown, M.D. Dr. Stead is supported by the Mayo Emergency Medicine Research Career Development Award and Mayo Clinic.
-----
www.fayettefrontpage.com
Fayette Front Page
Community News You Can Use
Fayetteville, Peachtree City, Tyrone
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
1:27 PM
0
comments
Labels: atlanta, blood flow, brain, fayette, fayette front page, fayetteville, georgia, georgia front page, ischemic, mayo, peachtree city, stroke, symptoms, treatment, tyrone
Friday, October 10, 2008
Mouse Studies Suggest Daily Dose of Ginkgo may Prevent Brain Cell Damage After a Stroke
Working with genetically engineered mice, researchers at Johns Hopkins have shown that daily doses of a standardized extract from the leaves of the ginkgo tree can prevent or reduce brain damage after an induced stroke.
The scientists, in a report published in Stroke, say their work lends support to other evidence that ginkgo biloba triggers a cascade of events that neutralizes free radicals known to cause cell death.
"It's still a large leap from rodent brains to human brains but these results strongly suggest that further research into the protective effects of ginkgo is warranted," says lead researcher Sylvain Doré, Ph.D., an associate professor in the Department of Anesthesiology and Critical Care Medicine. "If further work confirms what we've seen, we could theoretically recommend a daily regimen of ginkgo to people at high risk of stroke as a preventive measure against brain damage."
In the study, researchers gave ginkgo biloba EGb 761 - a lab-quality form of the extract - to normal mice and HO-1 knockout mice, mice lacking the gene that produces the enzyme heme oxygenase-1(HO-1). HO-1 breaks down heme, a common iron molecule found in blood, into carbon monoxide, iron and biliverdin. HO-1 has been shown to act as an antioxidant and have a protective effect against inflammation in animal models.
Doré and his team gave 100 milligrams per kilogram of EGb 761 extract orally once daily for seven days before inducing stroke in the mice by briefly blocking an artery to one side of the brain.
After stroke induction, the mice were tested for brain function and brain damage. One such test, for example, involves running patterns, another tests reaction to an external stimulus. Similar tests were conducted on mice that did not receive the ginkgo extract.
Neurobehavioral function was evaluated before the study and at 1, 2 and 22 hours after stroke using a four-point scale: (1) no deficit, (2) forelimb weakness, (3) inability to bear weight on the affected side, (4) no spontaneous motor activity.
Results showed that normal mice that were pretreated had 50.9 percent less neurological dysfunction and 48.2 percent smaller areas of brain damage than untreated mice. These positive effects did not exist in the HO-1 knockout mice.
"Our results suggest that some element or elements in ginkgo actually protect brain cells during stroke," says Doré.
Roughly 700,000 people experience a stroke in the United States annually. Of those, 87 percent have an ischemic stroke, which is caused by a blocked artery in the brain. Some brain damage occurs simply from the lack of blood getting to brain cells; however, it is known that an increase in the presence of free radicals at the site of an ischemic stroke - once the clot is cleared and the blood supply returns - is also a major cause of resulting brain cell damage. Free radicals are toxic oxygen molecules that are produced when cells die. According to Doré and his team, ginkgo increases HO-1 levels, and the antioxidant properties of this enzyme eliminate free radicals at the surrounding regions of the stroke site.
The only current treatment for ischemic stroke is to clear the clot with tissue plasminogen activator (tPA) or other means. This, however, offers no real protection against the cell damage that occurs when blood flow is restored.
"Ginkgo has long been touted for its positive effects on the brain and is even prescribed in Europe and Asia for memory loss," says Doré. "Now we have a possible understanding for how ginkgo actually works to protect neurons from damage."
Native to China, the ginkgo tree is grown as an ornamental shade tree in Australia, Southeast Asia, Europe, Japan and North America. It is commercially cultivated in France and the United States. It has a grey bark, reaches a height of 35 meters and a diameter of 3 to 4 meters. It has deciduous, fan-like leaves that are green, grey-yellow, brown or blackish.
Additional researchers include Sofiyan Saleem, Ph.D., and Hean Zhuang, M.D., of the Department of Anesthesiology and Critical Care Medicine, and Shyam Biswal, Ph.D., of the Department of Environmental Health Sciences, all from Johns Hopkins.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
8:31 AM
0
comments
Labels: atlanta, brain, fayette, fayette front page, fayetteville, georgia, georgia front page, ginkgo, johns hopkins, memory loss, peachtree city, stroke, study, tyrone
Monday, September 22, 2008
Indian Spice Reduces Size of Hemorrhagic Stroke
By: Amy Connell
Medical College of Georgia
2008 September 22
You might want to make curcumin part of your daily diet.
This active ingredient of the Indian curry spice, turmeric, not only lowers your chances of getting cancer and Alzheimer's disease, but may reduce the size of a hemorrhagic stroke, say Medical College of Georgia researchers.
Second-year medical student Jay McCracken is working with Dr. Krishnan Dhandapani, neuroscientist in the MCG School of Medicine, using animal models to study curcumin's effect on intracerebral hemorrhages, bleeding in the brain caused by ruptured vessels.
Patients with this type of stroke are often treated for symptoms – such as headache and nausea – with medications, but not the stroke itself. Invasive surgery to remove the clot is usually needed, but some patients may not be good candidates, says Mr. McCracken. About 17 percent of strokes are hemorrhagic, according to the American Stroke Association, and usually occur in people with high blood pressure.
"We found that curcumin significantly decreases the size of a blood clot, but we're not sure why it happens," says the Alpharetta native. He thinks it may be because curcumin is a potent anti-inflammatory and antioxidant. For the study, he dissolved the yellow powder, which gives turmeric its color, in corn oil and injected it into the abdomen of an animal model of hemorrhagic stroke three times over three hours. He suspects less may work and is trying to establish the optimal dose and timing.
Timing is critical for patients who often don't know they have had a stroke and may not be seen by a physician for several hours. "Usually, patients can experience other symptoms like seizures, vision or cognitive problems, so they come to the (emergency room) fairly quickly under most circumstances," says Dr. Dhandapani. "Many patients also arrive due to head trauma and are seen within an hour or so. However, treating these injuries, even after an hour, can be tricky."
Patients likely will need to get curcumin intravenously. The researchers believe it may also help prevent strokes; they intend to pursue this line of study with the idea of also making it available in a concentrated tablet form for those at-risk.
Mr. McCracken has worked on this project since May as part of the School of Medicine Dean's Summer Research Fellowship, which enables rising sophomore students to design and participate in cutting-edge basic and/or clinical research. He is among 25 students presenting their findings today from noon to 1 p.m. in the lobby of the Carl T. Sanders Research and Education Building. School of Medicine Dean D. Douglas Miller will recognize students for their work and talk about the importance and role of research.
Mr. McCracken will continue his research through the year. "I like the research, and I think it's good preparation for residency," he says. He hopes to pursue a neurosurgery residency after graduation.
A graduate of the University of Georgia, where he received biochemistry and microbiology degrees, it was a high school football injury that inspired Mr. McCracken to pursue medicine.
"I snapped my ankle, and when I met the orthopedic surgeon, I thought he was so nice and interesting," says Mr. McCracken. "And then, for an anatomy class, we had to interview someone in science or health care, and I chose my surgeon. He let me shadow him, and I thought it was the best thing in the world."
During his first year at MCG, Mr. McCracken found he really enjoyed anatomy, especially neuroanatomy.
"I think it's interesting and challenging," he says. "I've seen patients come in who have terrible tumors or hemorrhages, and neurosurgeons can change their life in a matter of hours. Patients come in expecting three months to live, and surgeons give them years to live. It's amazing."
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
2:01 PM
0
comments
Labels: anti-inflammatory, atlanta, augusta, clot, curcumin, fayette, fayette front page, georgia, georgia front page, hemorrhagic, medical college of georgia, peachtree city, stroke, turmeric
Tuesday, September 2, 2008
Study Indicates It's Never too Late for Exercise-- Even in Stroke Victims
People who walk on a treadmill even years after stroke damage can significantly improve their health and mobility, changes that reflect actual "rewiring" of their brains, according to research spearheaded at Johns Hopkins.
"This is great news for stroke survivors because results clearly demonstrate that long-term stroke damage is not immutable and that with exercise it's never too late for the brain and body to recover," says Daniel Hanley, M.D., professor of neurology at the Johns Hopkins University School of Medicine.
The study's results, published in Stroke: Journal of the American Heart Association, suggest that patients' brains may retain the capacity to rewire through a treadmill exercise program months or years after conventional physical therapy has ended.
The research was conducted by scientists at Johns Hopkins, the University of Maryland, and the Department of Veterans Affairs Maryland VA Medical Center at their Geriatric Research, Education, and Clinical Center (GRECC). Researchers at the GRECC, led by Richard F. Macko, M.D., and Andrew P. Goldberg, M.D., have developed treadmill therapy for stroke patients over the past decade. Investigators at all three institutions combined efforts to recruit 71 patients who had a stroke at least six months earlier, with an average time lapse of nearly four years. At the study's onset, half of the subjects could walk without assistance, while the rest used a cane, a walker or a wheelchair.
All of the subjects, separated into two random groups regardless of disability, were tested for mobility and aerobic capacity (also known as VO2 peak), a measure of cardiac fitness. Thirty-two patients drawn equally from both groups underwent functional magnetic resonance imaging (fMRI) to assess brain activity linked to moving their legs in a walking motion.
One group then participated in an exercise program that principally involved walking on a treadmill three times a week for up to 40 minutes, assisted by a supporting sling and tether if needed. Physical therapists assigned to each subject increased the intensity of the workouts over time by increasing the treadmills' speed and incline, though the workouts never taxed the patients beyond a moderate level of 60 percent VO2 peak.
With the second group of patients, therapists assisted the patients in performing stretching exercises for the same period of time.
After six months, patients were again tested for walking speed and VO2 peak, and the same group who had undergone fMRI was rescanned. Walking speed for the treadmill group increased 51 percent compared to about 11 percent faster for those in the stretching group. Ground walking speed among the treadmill exercisers increased 19 percent, compared to about 8 percent for the stretchers. The treadmill exercisers also were significantly more fit at study completion, with VO2 peak increasing by about 18 percent. VO2 peak decreased slightly in the stretching group.
Hoping to find evidence that improved brain activity was responsible for the results, the investigators analyzed the brain scans and found markedly increased metabolic activity in brainstem areas associated with walking among all the treadmill exercisers. Brain scans of patients in the stretching group showed no such changes.
"This suggests that the brain is responsible for the improvement we saw in patients' walking ability. It seems to be recruiting other regions to take on the job of areas damaged by stroke," says Andreas Luft, M.D., a visiting researcher who worked with all three institutions who conducted this study. Luft is currently a stroke attending physician and professor of neurorehabilitation at the University of Zurich in Switzerland.
Those patients with the most improvement in walking showed the strongest change in brain activity, though the researchers don't yet know whether these brain changes were caused by more walking or whether participants walked better because brain activity in these key areas increased. This question will be the focus of a future study.
Hanley says stroke patients are typically told to "learn to live with" their disabilities, unlike heart attack patients and others who are often prescribed lifestyle changes and exercise programs to help recover function. Most stroke rehabilitation programs focus on short-term improvement, ending just a few months after a patient has had a stroke. Consequently, over the following years, patients' functional improvement plateaus and their fitness often wanes-a factor that could increase the chance of a second stroke.
"Many stroke survivors believe there's nothing to be gained from further rehabilitation, but our results suggest that health and functional benefits from walking on a treadmill can occur even decades out from stroke," says Macko, professor of neurology at the University of Maryland School of Medicine, noting that one of the patients in the study had significant improvement 20 years after a stroke. "We believe exercise gives individuals a way to fight back against stroke disabilities."
-----
Fayette Front Page
Community News You Can Use
Fayetteville, Peachtree City, Tyrone
www.fayettefrontpage.com
www.georgiafrontpage.com
Posted by
Georgia Front Page.com
at
10:43 AM
0
comments
Labels: exercise, fayette, fayette county, fayette front page, fayetteville, georgia, georgia front page, peachtree city, stroke, tyrone
Saturday, July 19, 2008
More Children Becoming Stroke Victims
HHH Note: This story by Consumer Affairs really opened our eyes as to the potential dangers that some children at risk face. We thought you'd be interested in it as well.
Older adults are not the only people in danger of suffering a stroke. Increasingly, children are also stricken, according to the American Heart Association/American Stroke Association. In fact, it happens often enough....
Read the story.
Posted by
Georgia Front Page.com
at
5:00 AM
0
comments
Labels: brooks, children, dehydration, fayette, fayette county, fayette front page, fayetteville, heart association, peachtree city, risk, stroke, tyrone, woolsey